Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.77 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5246749 | 0.87 | CRHR1 (1.00) | CRHR1HSP90AA1HSP90AB1NR4A2MAPT | |
| SCHEMBL6726554 | 0.86 | CRHR1 (1.00) | CRHR1HSP90AA1HSP90AB1NR4A2KDM4E | |
| SCHEMBL6340859 | 0.82 | CRHR1 (0.56) | CRHR1HSP90AA1HSP90AB1KDM4EMAPT | |
| SCHEMBL1026984 | 0.79 | NR4A2 (0.65) | CRHR1HSP90AA1NR4A2CD38KDM4E | |
| SCHEMBL5210888 | 0.78 | CRHR1 (0.48) | CRHR1HSP90AA1HSP90AB1MAPT | |
| SCHEMBL6722252 | 0.77 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL7076625 | 0.76 | CRHR1 (0.65) | CRHR1NR4A2 | |
| SCHEMBL6306407 | 0.72 | CRHR1 (0.60) | CRHR1KDM4E | |
| SCHEMBL6215236 | 0.72 | TP53 (0.54) | NR4A2KDM4EMAPTL3MBTL1POLB | |
| SCHEMBL6834172 | 0.71 | CRHR1 (0.63) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299378-B1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-02-14 | — | — | EP | disclosed |
| US-7160900-B2 | Tetrahydropyridino or piperidino heterocyclic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-6852732-B2 | Tetrahydropyridino or piperidino heterocylic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20050009874-A1 | Tetrahydropyridin or piperidino heterocyclic derivatives | TAISHO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-20040121998-A1 | CRF antagonistic quino- and quinazolines | NEUROCRINE BIOSCIENCES, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20040034061-A1 | Tetrahydropyridino or piperidino heterocylic derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1299378-A4 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-0977737-B1 | CRF ANTAGONISTIC QUINO- AND QUINAZOLINES | JANSSEN PHARMACEUTICA NV (BE) | 2003-09-17 | — | — | EP | disclosed |
| US-6610678-B2 | Corticotropin-releasing factor antagonists; treating endocrine, psychiatric or neurologic disorders | HUANG CHARLES (US) | 2003-08-26 | — | — | US | disclosed |
| US-20030119818-A1 | CRF antagonistic quino-and quinazolines | HUANG CHARLES (US) | 2003-06-26 | — | — | US | disclosed |
| EP-1299378-A1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | Taisho Pharmaceutical Co. Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6482836-B1 | CRF antagonistic quino- and quinazolines | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-11-19 | — | — | US | disclosed |
| WO-2002002549-A1 | TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-10 | — | — | WO | disclosed |
| EP-0977737-A1 | CRF ANTAGONISTIC QUINO- AND QUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047874-A1 | CRF ANTAGONISTIC QUINO- AND QUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119818-A1 | CRF antagonistic quino-and quinazolines | CRHR1, HTR6, CRH | CRHR1 1/4885HSP90AA1 1830/4885HSP90AB1 2392/4885 |
| US-20040121998-A1 | CRF antagonistic quino- and quinazolines | CRHR1, HTR6, CRH | CRHR1 1/4885HSP90AA1 1830/4885HSP90AB1 2392/4885 |
| US-20050009874-A1 | Tetrahydropyridin or piperidino heterocyclic derivatives | CRHR1, CRHR2, VIPR1 | CRHR1 1/4885HSP90AA1 1243/4885HSP90AB1 1847/4885 |
| US-20040034061-A1 | Tetrahydropyridino or piperidino heterocylic derivatives | CRHR1, CRHR2, AGTR1 | CRHR1 1/4885HSP90AA1 1241/4885HSP90AB1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.